Home / Imipenem, Cilastatin and Relebactam / United States
US ATC J01DH56 · updated 2 Nov 2026
Imipenem, Cilastatin and Relebactam shortage in United States
Is there an Imipenem, Cilastatin and Relebactam shortage in United States?
Yes. As of 2 Nov 2026, 1 Imipenem, Cilastatin and Relebactam product is reported short in United States, the first since 9 Sep 2026. No return date has been given. Main reason: not stated.
Not reported short in any other country we track. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) discontinuation | Merck Sharp & Dohme LLC | 9 Sep 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).